Keros Therapeutics (NASDAQ:KROS) Earns Buy Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research note issued to investors on Friday, Benzinga reports. They currently have a $100.00 price target on the stock. HC Wainwright also issued estimates for Keros Therapeutics’ FY2028 earnings at $2.19 EPS. Other equities analysts also recently issued […]
More Stories
The Cigna Group (NYSE:CI) is Marco Investment Management LLC’s 10th Largest Position
Marco Investment Management LLC raised its position in The Cigna Group (NYSE:CI – Free Report) by 0.8% in the 3rd...
Crewe Advisors LLC Sells 1,297 Shares of AT&T Inc. (NYSE:T)
Crewe Advisors LLC reduced its position in shares of AT&T Inc. (NYSE:T – Free Report) by 14.6% in the third...
Cadence Design Systems, Inc. (NASDAQ:CDNS) Stake Lowered by Sompo Asset Management Co. Ltd.
Sompo Asset Management Co. Ltd. decreased its stake in Cadence Design Systems, Inc. (NASDAQ:CDNS – Free Report) by 4.7% during...
Estate Counselors LLC Acquires Shares of 10,785 Tenet Healthcare Co. (NYSE:THC)
Estate Counselors LLC purchased a new position in Tenet Healthcare Co. (NYSE:THC – Free Report) in the 3rd quarter, according...
Hartford Funds Management Co LLC Buys 42 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Hartford Funds Management Co LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 4.1%...
Blackstone Inc. (NYSE:BX) Shares Sold by Cerity Partners LLC
Cerity Partners LLC lessened its stake in shares of Blackstone Inc. (NYSE:BX – Free Report) by 0.1% in the third...